Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the Tourmaline-MM1 study of ixazomib in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Patients in the ixazomib, and oral proteosome inhibitor, plus lenalidomide and dexamethasone arm had a 6-month benefit on progression-free survival (PFS).
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.